Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

Background In the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations. Mesothelin (MSLN) is a candidate immunotherapy target; it is overexpressed by ovarian tumors and contributes to malignant/invasive phenotypes, maki...

Descrición completa

Detalles Bibliográficos

Principais autores:	Philip D Greenberg, Kristin G Anderson, Shannon K Oda, Breanna M Bates, Madison G Burnett, Magdalia Rodgers Suarez, Susan L Ruskin
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMJ Publishing Group 2022-03-01
Series:	Journal for ImmunoTherapy of Cancer
Acceso en liña:	https://jitc.bmj.com/content/10/3/e003959.full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!